ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,099.96
      1.02%
      US Tech 100
      17,244.80
      1.57%
      Dow Jones
      38,239.66
      0.40%
      Brent Oil
      88.165
      0.00%
      Bitcoin
      63,631.26
      0.35%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NYSE
      6. Johnson and Johnson (JNJ)

      7. Johnson and Johnson (JNJ) News

      JNJ

      Johnson and Johnson (JNJ)

      Johnson and Johnson
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NYSE:JNJ
      DateTimeSourceHeadlineSymbolCompany
      04/22/20244:30PMBusiness WireJohnson & Johnson to Participate in the Bernstein’s 40th Annual Strategic Decisions Conference (SDC)NYSE:JNJJohnson and Johnson
      04/19/20247:31AMIH Market NewsParamount’s Shares Surge Following Sony and Apollo’s Joint Bid; ISS Backs Berkshire Hathaway Director Re-election, and MoreNYSE:JNJJohnson and Johnson
      04/17/20246:59AMIH Market NewsUS Index Futures See Gains, Oil Prices DipNYSE:JNJJohnson and Johnson
      04/16/20244:33PMIH Market NewsU.S. Stocks Finish Lackluster Session Narrowly MixedNYSE:JNJJohnson and Johnson
      04/16/202410:46AMBusiness WireCORRECTING and REPLACING Johnson & Johnson Reports Q1 2024 ResultsNYSE:JNJJohnson and Johnson
      04/16/20249:52AMIH Market NewsJ&J’s Q1 2024 sales rise 2.3% to $21.4 billionNYSE:JNJJohnson and Johnson
      04/16/20249:09AMIH Market NewsDow Looks To Snap Six-Day Losing Streak As UnitedHealth SurgesNYSE:JNJJohnson and Johnson
      04/16/20247:19AMIH Market NewsU.S. Index Futures Signal Mixed Trading, Oil Prices DipNYSE:JNJJohnson and Johnson
      04/16/20247:18AMIH Market NewsEricsson Soars with 66% Net Profit Growth; Live Nation Under Antitrust Scrutiny in US, and More NewsNYSE:JNJJohnson and Johnson
      04/16/20246:25AMBusiness WireJohnson & Johnson Announces 62nd Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 4.2%NYSE:JNJJohnson and Johnson
      04/16/20246:20AMBusiness WireJohnson & Johnson Reports Q1 2024 ResultsNYSE:JNJJohnson and Johnson
      04/15/20244:38PMIH Market NewsU.S. Stocks Extend Sell-Off As Treasury Yields Surge After Retail Sales DataNYSE:JNJJohnson and Johnson
      04/08/20246:06PMBusiness WireJohnson & Johnson to Participate in the 2024 RBC Capital Markets Global Healthcare ConferenceNYSE:JNJJohnson and Johnson
      04/05/202411:21PMPR Newswire (US)CARVYKTI® is the First and Only BCMA-Targeted Treatment Approved by the U.S. FDA for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of TherapyNYSE:JNJJohnson and Johnson
      04/05/20242:55PMPR Newswire (US)ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Shockwave Medical, Inc.NYSE:JNJJohnson and Johnson
      04/05/20247:38AMIH Market NewsApple Terminates 614 Employees, Disney Unveils June Crackdown on Password Sharing, and More UpdatesNYSE:JNJJohnson and Johnson
      04/05/20246:31AMBusiness WireJohnson & Johnson to Acquire Shockwave MedicalNYSE:JNJJohnson and Johnson
      04/04/20246:01PMBusiness WireJohnson & Johnson Recommends Shareholders Reject “Mini-Tender” Offer by TRC Capital Investment CorporationNYSE:JNJJohnson and Johnson
      04/02/20244:30PMBusiness WireJohnson & Johnson to Participate in the BofA Securities Health Care ConferenceNYSE:JNJJohnson and Johnson
      03/28/20249:48AMIH Market NewsWalgreens Slashes Annual Profit Forecast; MillerKnoll Nosedives 17% on Bleak 4Q Outlook, and Latest NewsNYSE:JNJJohnson and Johnson
      03/27/20246:54AMIH Market NewsGameStop Shares Tumble 20% in Pre-Market Trading Amid Revenue Decline, Direct Digital Plummets 42%, and More NewsNYSE:JNJJohnson and Johnson
      03/12/20249:15AMGlobeNewswire Inc.Artelo Biosciences Selected as a Finalist in Johnson & Johnson’s Innovation ChallengeNYSE:JNJJohnson and Johnson
      03/11/20244:30PMBusiness WireJohnson & Johnson to Host Investor Conference Call on First-Quarter ResultsNYSE:JNJJohnson and Johnson
      03/07/20244:58PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:JNJJohnson and Johnson
      03/07/20244:58PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:JNJJohnson and Johnson
      03/07/20248:33AMBusiness WireJohnson & Johnson Completes Acquisition of AmbrxNYSE:JNJJohnson and Johnson
      03/06/20243:42PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:JNJJohnson and Johnson
      03/01/20243:59PMPR Newswire (US)RYBREVANT® (amivantamab-vmjw) in Combination With Chemotherapy Is the First FDA Approved Therapy for First-line Treatment of Patients With Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion MutationsNYSE:JNJJohnson and Johnson
      02/20/20245:58PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:JNJJohnson and Johnson
      02/20/20245:56PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:JNJJohnson and Johnson
       Showing the most relevant articles for your search:NYSE:JNJ